Hexarelin vs Ipamorelin China Supplier Guide

Create independent molecular specifications

Write separate RFQ lines for Hexarelin Acetate and Ipamorelin with each controlled name, molecular identity reference, material form, purity target, nominal content, quantity and Research Use Only status. Do not infer equivalence from the fact that both are commonly placed in growth-peptide catalogs. Ask the supplier to map its internal SKU to the exact molecule on the quotation, COA, analytical sample, vial label and packing list. A proposed substitution requires a fresh technical review and explicit written buyer approval.

Compare overlapping strengths without losing identity

Both catalog families include 2mg and 5mg units, while Ipamorelin also includes 10mg. Build a matrix with product, strength, vial count, units per kit, total nominal material, content tolerance, parent lot, finished lot and price basis. Equal strength labels can make warehouse swaps difficult to notice. Require distinct product codes and full-name labels, and ask whether multiple strengths share a parent lot and how their filling genealogy and reconciliation are retained.

Require molecule-specific HPLC and MS evidence

Review a separate analytical package for each offered molecule and lot. HPLC can support chromatographic purity and mass spectrometry can support identity, but neither report should be used beyond its method scope. Check expected molecular information, sample ID, complete chromatogram, integration, test date, method reference, report number and authorization. A report for a CJC-1295 plus Ipamorelin blend cannot qualify standalone Ipamorelin, and an Ipamorelin report cannot qualify Hexarelin.

Verify vial content separately from purity

Ask which quantitative method or controlled filling record supports every 2mg, 5mg or 10mg label and what tolerance applies. Confirm whether the stated amount means net peptide content or total lyophilized mass. If one parent lot is divided into several strengths, obtain quantity reconciliation across issued, filled, rejected and remaining material. Keep identity, chromatographic purity and quantitative content in separate acceptance columns so a favorable purity percentage cannot imply an untested amount.

Control mixed-order packaging and receiving

For orders containing both peptides, require a packing list organized by full product name, strength and lot. Approve label proofs and ask how line clearance, component issuance, picking checks and final reconciliation prevent swaps. Confirm vial and closure, units per kit, secondary protection, released stock, MOQ and realistic release timing. Receiving staff should inspect representative units and quarantine any name, strength, lot, seal or quantity inconsistency until a documented investigation is approved.

Build one comparable wholesale RFQ matrix

Send every candidate the same fields: controlled identity, strength, vial count, total material, target purity or composition, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, MOQ, lead time and shipping term. Mark missing answers as exceptions instead of filling gaps with assumptions. Separate testing, setup, customization and transport costs from recurring unit price. A standardized matrix gives scientific, purchasing and quality reviewers one auditable record and prevents an incomplete offer from appearing cheaper simply because it describes less work.

Apply a batch-focused quality-control review

Define every required attribute, acceptance criterion, method and record before purchase. Use the quality-control framework to connect each supplier claim to evidence and its method scope. Check sample identifiers, dates, report numbers, units and lot relationships across the complete reports. Batch-specific evidence is more decision-useful than a representative certificate. Preserve original files, record revisions and investigate contradictions before approving shipment. Where risk warrants, arrange independent testing under a documented sampling and custody plan.

Create a documentation gate before dispatch

List the required batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ and purchase order. Reconcile product, strength, lot, quantity and revision across records with the documentation guide. Require replacement documents when the offered lot changes. The importer remains responsible for current destination requirements. Research-use wording improves clarity but cannot guarantee customs entry or replace destination-specific legal and broker review.

Verify supplier and batch ownership

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A trading or coordination company can work with qualified partners, but roles and accountability must be transparent. Ask who owns the batch record, authorizes release, handles deviations and provides corrective action. Require advance notification when a critical party changes. Business-registration evidence supports identity but does not replace technical qualification of the offered lot.

Plan logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject guarantees of customs clearance or misleading declarations. On receipt, document package condition, seals, product, strength, lot and quantity, then connect internal inventory to the supplier batch. Store according to the applicable approved specification and quarantine unexplained damage, label conflicts, quantity differences or excursions until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification and evidence expectations planned for wholesale scale. Assess document accuracy, packaging, delivery time, communication and corrective response. Update a supplier scorecard from observed performance rather than catalog breadth or claims. For every new lot, repeat the batch review and approve current documents before dispatch. Require notification before changes to material specification, manufacturing, testing, filling, labels, packaging or other buyer-approved conditions.

Related products and same-category guides

• Hexarelin Acetate 2mg
• Hexarelin Acetate 5mg
• Ipamorelin 2mg
• Ipamorelin 5mg
• Ipamorelin 10mg
• GHRP-2 vs GHRP-6 Buyer Guide
• CJC-1295 + Ipamorelin Guide

Frequently asked questions